- Home
- GNTA vs IGC Comparison
GNTA vs IGC Comparison
Compare GNTA & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | IGC |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 28.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | GNTA | IGC |
|---|---|---|
| Price | $1.00 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | ★ 625.8K | 346.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.24 |
| 52 Week High | $10.00 | $0.50 |
Technical Indicators
Market Signals| Indicator | GNTA | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 46.95 |
| Support Level | $0.71 | N/A |
| Resistance Level | $1.70 | $0.32 |
| Average True Range (ATR) | 0.11 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 85.53 | 65.00 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.